Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Interest Expenses (2021 - 2025)

Serina Therapeutics' Interest Expenses history spans 5 years, with the latest figure at $6000.0 for Q3 2025.

  • For Q3 2025, Interest Expenses fell 62.5% year-over-year to $6000.0; the TTM value through Sep 2025 reached $32000.0, up 100.83%, while the annual FY2024 figure was $526000.0, 5.73% down from the prior year.
  • Interest Expenses for Q3 2025 was $6000.0 at Serina Therapeutics, down from $9000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $978000.0 in Q4 2022 and bottomed at -$4.4 million in Q4 2023.
  • The 5-year median for Interest Expenses is $108000.0 (2023), against an average of $5666.7.
  • The largest annual shift saw Interest Expenses skyrocketed 223.86% in 2022 before it crashed 546.83% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $285000.0 in 2021, then soared by 243.16% to $978000.0 in 2022, then plummeted by 546.83% to -$4.4 million in 2023, then soared by 100.39% to $17000.0 in 2024, then tumbled by 64.71% to $6000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Interest Expenses are $6000.0 (Q3 2025), $9000.0 (Q2 2025), and $17000.0 (Q4 2024).